ARYx Therapeutics Schedules First Quarter 2010 Results Conference Call

FREMONT, Calif.--(BUSINESS WIRE)-- ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced today that a conference call to discuss first quarter 2010 results and to provide a general business update will be held on Thursday, May 13, 2010 at 8:00 a.m. Pacific Time.

The dial-in information for the call is as follows:

Dial In: 877-303-6148
Dial In (International): 678-809-1064
Passcode (if requested): 73237700

Preregistration is not required. This call is also being Webcast and will be available live via the Internet by accessing the ARYx Therapeutics’ Website at www.aryx.com. Replays of the call will be available through June 18, 2010 at ARYx’s Website.

About ARYx Therapeutics, Inc.

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical development: an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (ATI-5923); a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (ATI-2042); and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit ARYx’s Website at www.aryx.com for additional information.



CONTACT:

ARYx Therapeutics, Inc.
David Nagler, 510-585-2200 ext. 211

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.